Genomma Lab Internacional SAB, founded in 2000 and headquartered in Mexico City, is a prominent pharmaceutical and personal care company focused on the development, manufacturing, and marketing of over-the-counter products. The company specializes in a diverse portfolio that includes dermatological, oral, and nutritional products, catering to both domestic and international markets.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| LABBMM 12.33% 2027-03-30 MXNGenomma Lab Internacional SAB | Mexico | 2027-03-30 | 12.330 | 11.26 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Genomma Lab has been active in the bond market since 2015, issuing its first bond porfolios to support growth initiatives and expand its market reach. Notable transactions include a significant issuance in 2020 amounting to $400 million, aimed at refinancing existing debt, which indicated strong investor confidence reflected in a 5% yield, competitive within the healthcare sector. The company’s bonds are structured with features such as call options, which enhance flexibility for corporate financial strategies, and recent ratings upgrades from credit agencies signal improved creditworthiness amidst a recovering economy.